Polymorphisms in p53 and the p53 pathway: Roles in cancer susceptibility and response to treatment

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 3, 2009, Pages 440-453

  Hrstka, Roman ^a   Coates, Philip J ^b   Vojtesek, Borivoj ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

MDM2; p53; Polymorphism; R72P SNP

Indexed keywords

PROTEIN P53;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; EXON; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; EXONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASMS; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63049102513     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00634.x     Document Type: Review

References (131)

1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991 351 : 453 6.
2. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 329 : 1318 27.
3. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000 408 : 307 10.
4. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci. 2001 114 : 4139 40.
5. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol. 2007 39 : 1476 82.
6. Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci. 2005 96 : 729 37.
7. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, Sicotte H, Staats B, Acharya M, Crenshaw A, Eckert A, Puri V, Gerhard DS, Chanock SJ. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. 2006 34 : D617 21.
8. Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet. 1993 53 : 752 9.
9. Li X, Dumont P, Della Pietra A, Shetler C, Murphy ME. The codon 47 polymorphism in p53 is functionally significant. J Biol Chem. 2005 280 : 24245 51.
10. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol. 1986 6 : 4650 6.
11. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987 7 : 961 3.
12. Baptiste N, Friedlander P, Chen X, Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 2002 21 : 9 21.
13. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994 44 : 266 70.
14. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet. 2006 38 : 1133 41.
15. Dumont P, Leu JI, Della Pietra AC, 3rd., George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003 33 : 357 65.
16. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003 3 : 387 402.
17. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelln WG Jr. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000 25 : 47 54.
18. Tada M, Furuuchl K, Kaneda M Matsumoto J, Takahashl M, Hlral A Mltsumoto Y, Iggo RD, Moriuchi T. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdomi-nant mutants. Carcinogenesis. 2001 22 : 515 7.
19. Wang Y, Krlngen P, Krlstensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Halnaut P, Trope CG, Abeler VM Nesland JM, Borresen-Dale AL, Helland A. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 2004 24 : 21 34.
20. Sullivan A, Syed N, Gasco M Bergamaschl D, Trigiante G, Attard M Hlller L, Farrell PJ, Smith P, Lu X, Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004 23 : 3328 37.
21. Slddlque M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006 25 : 3489 500.
22. Storey A, Thomas M, Kallta A, Harwood C Gardlol D, Mantovanl F, Breuer J, Leigh IM, Matlashewskl G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998 393 : 229 34.
23. Mltra S, Mlsra C, Singh RK, Panda CK Roychoudhury S. Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J Clin Pathol. 2005 58 : 26 31.
24. Santos AM, Sousa H, Catarlno R, Plnto D Perelra D, Vasconcelos A, Matos A Lopes C, Medeiros R. TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Cancer Genet Cytogenet 2005 159 : 143 7.
25. Klug SJ, Wilmotte R, Santos C, Almonte M, Herrero R, Guerrero I, Caceres E Pelxoto-Gulmaraes D, Lenolr G, Halnaut P, Walboomers JM, Munoz N. TP53 polymorphism, HPV infection, and risk of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2001 10 : 1009 12.
26. Ueda M, Hung YC, Teral Y, Kanda K Takehara M, Yamashlta H, Yamaguchl H, Akise D, Yasuda M, Nishiyama K, Ueki M. Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells. Hum Cell. 2003 16 : 241 51.
27. Buyru N, Tigli H, Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep. 2003 10 : 711 4.
28. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Borresen-Dale AL. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002 11 : 1684 8.
29. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett. 2005 222 : 57 65.
30. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, von Smitten K, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res. 2005 11 : 5098 103.
31. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet. 2007 173 : 38 42.
32. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007 12 : 303 12.
33. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS. p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev. 1997 6 : 105 12.
34. Liu G, Miller DP, Zhou W, Thurston SW, Fan R, Xu LL, Lynch TJ, Wain JC, Su L, Christiani DC. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res. 2001 61 : 8718 22.
35. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000 9 : 1037 42.
36. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene. 2002 21 : 6898 907.
37. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res. 2004 10 : 5845 9.
38. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2002 183 : 123 30.
39. Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis. 2005 26 : 1770 3.
40. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res. 2005 11 : 7328 33.
41. Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, Silva A, Amorim J, Lopes JM, Reis RM. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet. 2008 180 : 14 9.
42. Lozano G, Levine AJ. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog. 1991 4 : 3 9.
43. Varley JM, McGown G, Thorncroft M, White GR, Tricker KJ, Kelsey AM, Birch JM, Evans DG. A novel TP53 splicing mutation in a Li-Fraumeni syndrome family: a patient with Wilms' tumour is not a mutation carrier. Br J Cancer. 1998 78 : 1081 3.
44. Lazar V, Hazard F, Bertin F, Janin N, Bellet D, Bressac B. Simple sequence repeat polymorphism within the p53 gene. Oncogene. 1993 8 : 1703 5.
45. Hillebrandt S, Streffer C, Demidchik EP, Biko J, Reiners C. Polymorphisms in the p53 gene in thyroid tumours and blood samples of children from areas in Belarus. Mutat Res. 1997 381 : 201 7.
46. McDaniel T, Carbone D, Takahashi T, Chumakov P, Chang EH, Pirollo KF, Yin J, Huang Y, Meltzer SJ. The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res. 1991 19 : 4796.
47. Chumakov PM, Jenkins JR. BstNI/NciI polymorphism of the human p53 gene (TP53). Nucleic Acids Res. 1991 19 : 6969.
48. Runnebaum IB, Tong XW, Konig R, Zhao H, Korner K, Atkinson EN, Kreienberg R, Kieback DG, Hong Z. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet. 1995 345 : 994.
49. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008 8 : 32.
50. Campbell IG, Eccles DM, Dunn B, Davis M, Leake V. p53 polymorphism in ovarian and breast cancer. Lancet. 1996 347 : 393 4.
51. Kim JM, Lee OY, Lee CG, Kwon SJ, Kim KS, Moon W, Koh DH, Lee HL, Yoon BC, Choi HS, Hahm JS, Lee MH, Lee DH. [p53 Codon 72 and 16-bp duplication polymorphisms of gastric cancer in Koreans]. Korean J Gastroenterol. 2007 50 : 292 8.
52. Lancaster JM, Brownlee HA, Wiseman RW, Taylor J. p53 polymorphism in ovarian and bladder cancer. Lancet. 1995 346 : 182.
53. Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA, Runnebaum IB. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer. 1999 81 : 179 83.
54. Mavridou D, Gornall R, Campbell IG, Eccles DM. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br J Cancer. 1998 77 : 676 7.
55. Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K, Rotter V. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol. 1995 14 : 983 90.
56. Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, Shields PG, Modali R, Turner BC. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res. 2000 60 : 1062 9.
57. Marsh A, Spurdle AB, Turner BC, Fereday S, Thorne H, Pupo GM, Mann GJ, Hopper JL, Sambrook JF, Chenevix-Trench G. The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Res. 2001 3 : 346 9.
58. Fiszer-Maliszewska L, Kazanowska B, Kusnierczyk P, Manczak M, Niepieklo W, Pochron-Zeman B, Nowakowska B. Is p53 intronic variant G13964C associated with predisposition to cancer? J Appl Genet. 2003 44 : 547 52.
59. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, Spitz MR. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000 92 : 1764 72.
60. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst. 2002 94 : 681 90.
61. Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Beckman G, Beckman L. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis. 1995 16 : 2233 6.
62. Khaliq S, Hameed A, Khaliq T, Ayub Q, Qamar R, Mohyuddin A, Mazhar K, Qasim-Mehdi S. P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test. 2000 4 : 23 9.
63. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L, Beckman G. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis. 1995 16 : 1461 4.
64. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996 17 : 1313 6.
65. Biros E, Kalina I, Kohut A, Bogyiova E, Salagovic J, Sulla I. Allelic and haplotype frequencies of the p53 polymorphisms in brain tumor patients. Physiol Res. 2002 51 : 59 64.
66. Birgander R, Sjalander A, Zhou Z, Fan C, Beckman L, Beckman G. p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered. 1996 46 : 49 54.
67. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Greco G, Mussi A, Donati V, Fontanini G. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Invest. 2008 26 : 168 72.
68. Lamolle G, Marin M, Alvarez-Valin F. Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers. Mutat Res. 2006 600 : 102 12.
69. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007 315 : 525 8.
70. Kanaya S, Yamada Y, Kinouchi M, Kudo Y, Ikemura T. Codon usage and tRNA genes in eukaryotes: correlation of codon usage diversity with translation efficiency and with CG-dinucleotide usage as assessed by multivariate analysis. J Mol Evol. 2001 53 : 290 8.
71. Sharp PM, Li WH. Codon usage in regulatory genes in Escherichia coli does not reflect selection for 'rare' codons. Nucleic Acids Res. 1986 14 : 7737 49.
72. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res. 2004 64 : 7647 54.
73. Holmila R, Fouquet C, Cadranel J, Zalcman G, Soussi T. Splice mutations in the p53 gene: case report and review of the literature. Hum Mutat. 2003 21 : 101 2.
74. Warneford SG, Witton LJ, Townsend ML, Rowe PB, Reddel RR, Dalla-Pozza L, Symonds G. Germ-line splicing mutation of the p53 gene in a cancer-prone family. Cell Growth Differ. 1992 3 : 839 46.
75. Gorlov IP, Gorlova OY, Frazier ML, Amos CI. Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs). Mutat Res. 2004 554 : 175 83.
76. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002 3 : 285 98.
77. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003 31 : 3568 71.
78. Pfeifer GP. p53 mutational spectra and the role of methylated CpG sequences. Mutat Res. 2000 450 : 155 66.
79. Kouidou S, Malousi A, Maglaveras N. Methylation and repeats in silent and nonsense mutations of p53. Mutat Res. 2006 599 : 167 77.
80. Felix CA, Brown DL, Mitsudomi T, Ikagaki N, Wong A, Wasserman R, Womer RB, Biegel JA. Polymorphism at codon 36 of the p53 gene. Oncogene. 1994 9 : 327 8.
81. Finlan LE, Hupp TR. p63: the phantom of the tumor suppressor. Cell Cycle. 2007 6 : 1062 71.
82. Barrow LL, van Bokhoven H, Daack-Hirsch S, Andersen T, van Beersum SE, Gorlin R, Murray JC. Analysis of the p63 gene in classical EEC syndrome, related syndromes, and non-syndromic orofacial clefts. J Med Genet. 2002 39 : 559 66.
83. Muller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T. One, two, three-p53, p63, p73 and chemosensitivity. Drug Resist Updat. 2006 9 : 288 306.
84. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP, Romani M. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 2002 9 : 246 51.
85. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med. 2002 196 : 765 80.
86. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res. 2004 2 : 371 86.
87. Coates PJ. Regulating p73 isoforms in human tumours. J Pathol. 2006 210 : 385 9.
88. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997 90 : 809 19.
89. Li G, Sturgis EM, Wang LE, Chamberlain RM, Amos CI, Spitz MR, El-Naggar AK, Hong WK, Wei Q. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2004 25 : 1911 6.
90. Li G, Wang LE, Chamberlain RM, Amos CI, Spitz MR, Wei Q. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 2004 64 : 6863 6.
91. Niwa Y, Hirose K, Matsuo K, Tajima K, Ikoma Y, Nakanishi T, Nawa A, Kuzuya K, Tamakoshi A, Hamajima N. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett. 2005 219 : 183 90.
92. Ryan BM, McManus R, Daly JS, Carton E, Keeling PW, Reynolds JV, Kelleher D. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer. 2001 85 : 1499 503.
93. Hu Z, Miao X, Ma H, Tan W, Wang X, Lu D, Wei Q, Lin D, Shen H. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 2005 114 : 455 60.
94. Li H, Yao L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Dong B, Lin B, Xie Y. Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival. Carcinogenesis. 2007 28 : 372 7.
95. Pena C, Garcia JM, Dominguez G, Silva J, Garcia V, Carcereny E, Vargas J, Provencio M, Espana P, Bonilla F. Intronic deletion affecting a negative regulatory region of TP73 is related to breast and colorectal carcinomas. Genes Chromosomes Cancer. 2004 39 : 257 62.
96. Dominguez G, Pena C, Silva J, Garcia JM, Garcia V, Rodriguez R, Cantos B, Citores MJ, Espana P, Bonilla F. The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas. J Pathol. 2006 210 : 390 7.
97. Toledo F, Wahl GM. Regulating the p53 pathway: in vitrohypotheses, in vivo veritas. Nat Rev Cancer. 2006 6 : 909 23.
98. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005 65 : 5481 4.
99. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006 43 : 531 3.
100. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D'Andrea E, Nitti D, Amadori A, Bertorelle R. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006 98 : 285 8.
101. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, Verhoef S, Van't Veer LJ. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet. 2007 15 : 110 4.
102. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst. 2006 98 : 911 9.
103. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dork T, Van't Veer LJ. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res. 2007 67 : 9584 90.
104. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006 66 : 5104 10.
105. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 2007 26 : 1317 23.
106. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 119 : 591 602.
107. Krekac D, Brozkova K, Knoflickova D, Hrstka R, Muller P, Nenutil R, Vojtesek B. MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology. 2008 74 : 84 7.
108. Hartmann E, Fernandez V, Stoecklein H, Hernandez L, Campo E, Rosenwald A. Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. Haematologica. 2007 92 : 574 5.
109. O'Connor PM. Mammalian G1 and G2 phase checkpoints. Cancer Sur v. 1997 29 : 151 82.
110. Mousses S, Ozcelik H, Lee PD, Malkin D, Bull SB, Andrulis IL. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet. 1995 4 : 1089 92.
111. Birgander R, Sjalander A, Saha N, Spitsyn V, Beckman L, Beckman G. The codon 31 polymorphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups. Hum Hered. 1996 46 : 148 54.
112. Su L, Sai Y, Fan R, Thurston SW, Miller DP, Zhou W, Wain JC, Lynch TJ, Liu G, Christiani DC. P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Lung Cancer. 2003 40 : 259 66.
113. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006 25 : 1602 11.
114. Shih CM, Lin PT, Wang HC, Huang WC, Wang YC. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res. 2000 91 : 9 15.
115. Powell BL, van Staveren IL, Roosken P, Grieu F, Berns EM, Iacopetta B. Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis. 2002 23 : 311 5.
116. Facher EA, Becich MJ, Deka A, Law JC. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer. 1997 79 : 2424 9.
117. Contente A, Dittmer A, Koch MC, Roth J, Dobbelstein M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat Genet. 2002 30 : 315 20.
118. Fegan C, Starczynski J, Pratt G, Pepper C. The role of the bax gene polymorphism G(-248)A in chronic lymphocytic leukemia. Leukemia. 2006 20 : 1460 1.
119. Saxena A, Moshynska O, Sankaran K, Viswanathan S, Sheridan DP. Association of a novel single nucleotide polymorphism, G(-248)A, in the 5'-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. Cancer Lett. 2002 187 : 199 205.
120. Kidd LR, Coulibaly A, Templeton TM, Chen W, Long LO, Mason T, Bonilla C, Akereyeni F, Freeman V, Isaacs W, Ahaghotu C, Kittles RA. Germline BCL-2 sequence variants and inherited predisposition to prostate cancer. Prostate Cancer Prostatic Dis. 2006 9 : 284 92.
121. Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, Sagiv SK, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007 28 : 2548 51.
122. Ueda M, Hung YC, Terai Y, Yamaguchi H, Saito J, Nunobiki O, Noda S, Ueki M. Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol. 2005 98 : 129 33.
123. Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P, Zhou Y, Lin D. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet. 2005 42 : 479 84.
124. Tomso DJ, Inga A, Menendez D, Pittman GS, Campbell MR, Storici F, Bell DA, Resnick MA. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci USA. 2005 102 : 6431 6.
125. Resnick MA, Tomso D, Inga A, Menendez D, Bell D. Functional diversity in the gene network controlled by the master regulator p53 in humans. Cell Cycle. 2005 4 : 1026 9.
126. Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA, Schonfelder G. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci USA. 2006 103 : 1406 11.
127. Menendez D, Inga A, Snipe J, Krysiak O, Schonfelder G, Resnick MA. A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. Mol Cell Biol. 2007 27 : 2590 600.
128. Vikhanskaya F, Siddique MM, Kei Lee M, Broggini M, Sabapathy K. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res. 2005 11 : 4348 56.
129. Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett. 2004 210 : 197 203.
130. Sakiyama T, Kohno T, Mimaki S, Ohta T, Yanagitani N, Sobue T, Kunitoh H, Saito R, Shimizu K, Hirama C, Kimura J, Maeno G, Hirose H, Eguchi T, Saito D, Ohki M, Yokota J. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer. 2005 114 : 730 7.
131. Parhar P, Ezer R, Shao Y, Allen JC, Miller DC, Newcomb EW. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res. 2005 137 : 98 103.